Literature DB >> 22491251

PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis.

Margarite L Tarrio1, Nir Grabie, De-xiu Bu, Arlene H Sharpe, Andrew H Lichtman.   

Abstract

PD-1, a member of the CD28 family of immune regulatory molecules, is expressed on activated T cells, interacts with its ligands, PD-L1/B7-H1 and PD-L2/B7-DC, on other cells, and delivers inhibitory signals to the T cell. We studied the role of this pathway in modulating autoreactive T cell responses in two models of myocarditis. In a CD8(+) T cell-mediated adoptive transfer model, we found that compared with Pd1(+/+) CD8(+) T cells, Pd1(-/-) CD8(+) T cells cause enhanced disease, with increased inflammatory infiltrate, particularly rich in neutrophils. Additionally, we show enhanced proliferation in vivo and enhanced cytotoxic activity of PD-1-deficient T lymphocytes against myocardial endothelial cells in vitro. In experimental autoimmune myocarditis, a disease model dependent on CD4(+) T cells, we show that mice lacking PD-1 develop enhanced disease compared with wild-type mice. PD-1-deficient mice displayed increased inflammation, enhanced serum markers of myocardial damage, and an increased infiltration of inflammatory cells, including CD8(+) T cells. Together, these studies show that PD-1 plays an important role in limiting T cell responses in the heart.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22491251      PMCID: PMC3345066          DOI: 10.4049/jimmunol.1200389

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2.

Authors:  Y Furukawa; D A Mandelbrot; P Libby; A H Sharpe; R N Mitchell
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis.

Authors:  K S Kim; M D Denton; A Chandraker; A Knoflach; R Milord; A M Waaga; L A Turka; M E Russell; R Peach; M H Sayegh
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy.

Authors:  G Christian Baldeviano; Jobert G Barin; Monica V Talor; Sachin Srinivasan; Djahida Bedja; Dongfeng Zheng; Kathleen Gabrielson; Yoichiro Iwakura; Noel R Rose; Daniela Cihakova
Journal:  Circ Res       Date:  2010-04-08       Impact factor: 17.367

Review 4.  Cancer immunotherapy comes of age.

Authors:  Suzanne L Topalian; George J Weiner; Drew M Pardoll
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

5.  Cutting edge: CTLA-4--B7 interaction suppresses Th17 cell differentiation.

Authors:  Haiyan Ying; Lifen Yang; Guilin Qiao; Zhenping Li; Li Zhang; Fei Yin; Dong Xie; Jian Zhang
Journal:  J Immunol       Date:  2010-07-02       Impact factor: 5.422

6.  PD-1 deficiency results in the development of fatal myocarditis in MRL mice.

Authors:  Jian Wang; Il-Mi Okazaki; Taku Yoshida; Shunsuke Chikuma; Yu Kato; Fumio Nakaki; Hiroshi Hiai; Tasuku Honjo; Taku Okazaki
Journal:  Int Immunol       Date:  2010-04-21       Impact factor: 4.823

7.  Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.

Authors:  De-xiu Bu; Margarite Tarrio; Elena Maganto-Garcia; George Stavrakis; Goro Tajima; James Lederer; Petr Jarolim; Gordon J Freeman; Arlene H Sharpe; Andrew H Lichtman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-10       Impact factor: 8.311

Review 8.  The PD-1 pathway in tolerance and autoimmunity.

Authors:  Loise M Francisco; Peter T Sage; Arlene H Sharpe
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

9.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Authors:  Kaori Sakuishi; Lionel Apetoh; Jenna M Sullivan; Bruce R Blazar; Vijay K Kuchroo; Ana C Anderson
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

10.  PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction.

Authors:  Yan Zhang; Ying Zhou; Jingsheng Lou; Jinbao Li; Lulong Bo; Keming Zhu; Xiaojian Wan; Xiaoming Deng; Zailong Cai
Journal:  Crit Care       Date:  2010-11-30       Impact factor: 9.097

View more
  94 in total

1.  Analysis of PD-1 and Tim-3 expression on CD4+ T cells of patients with rheumatoid arthritis; negative association with DAS28.

Authors:  Zohreh Koohini; Hadi Hossein-Nataj; Maryam Mobini; Aref Hosseinian-Amiri; Alireza Rafiei; Hossein Asgarian-Omran
Journal:  Clin Rheumatol       Date:  2018-04-07       Impact factor: 2.980

Review 2.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

Review 3.  Cardiotoxicity of Immune Checkpoint Inhibitors.

Authors:  Lili Zhang; Maeve Jones-O'Connor; Magid Awadalla; Daniel A Zlotoff; Paaladinesh Thavendiranathan; John D Groarke; Alexandra-Chloe Villani; Alexander R Lyon; Tomas G Neilan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-06-08

Review 4.  Cardiac Autoimmunity: Myocarditis.

Authors:  William Bracamonte-Baran; Daniela Čiháková
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Authors:  Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

Review 6.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

Review 7.  Adaptive immune cells in calcific aortic valve disease.

Authors:  Michael A Raddatz; Meena S Madhur; W David Merryman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-03       Impact factor: 4.733

Review 8.  T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases.

Authors:  Eoin F McKinney; Kenneth Gc Smith
Journal:  Immunol Cell Biol       Date:  2016-11       Impact factor: 5.126

Review 9.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

10.  Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.

Authors:  Robert Gibson; Jess Delaune; Anita Szady; Merry Markham
Journal:  BMJ Case Rep       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.